Jan 19, 2016 7:00am EST U.S. Patent & Trademark Office Issues Notice of Allowance for Can-Fite's Sexual Dysfunction Drug CF602
Jan 11, 2016 7:00am EST Can-Fite Announces 2016 Clinical Milestones for its Pipeline of Drugs in Six Indications
Jan 05, 2016 7:00am EST Can-Fite Submits Phase III Protocol to IRB for CF101 in the Treatment of Rheumatoid Arthritis
Dec 17, 2015 7:00am EST Can-Fite's CF101 Granted Patent in Japan for Intraocular Pressure a Key Cause of Glaucoma
Dec 07, 2015 7:00am EST Can-Fite Subsidiary, OphthaliX, Announces Completion of Patient Enrollment in Phase II Glaucoma Study for CF101
Nov 23, 2015 7:00am EST Can-Fite Announces Compelling Pre-Clinical Data on CF102 in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Oct 26, 2015 7:00am EDT Can-Fite to Participate in BIO-Europe Partnering Conference on November 2-5, 2015 in Munich, Germany
Oct 22, 2015 7:00am EDT New Study Demonstrates CF602 Mechanism of Action to Improve Sexual Dysfunction
